Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Section 5 of 6

Economic information and modeling report

28 evidence topics · 23 sources

Modeling overview

Summary: published economic evidence for comparators

No cost-effectiveness analysis or budget impact model of palazestrant has been published, and no price exists. Published evaluations address the comparators. For elacestrant, a U.S. third-party payer partitioned survival model over 10 years using EMERALD data estimated incremental cost-effectiveness ratios of $8,672,360 per QALY gained compared with standard of care in the overall population and $2,900,560 per QALY gained compared with fulvestrant in the ESR1-mutation subgroup, with a 0% probability of cost-effectiveness at $150,000 per QALY gained. NICE recommends elacestrant for ESR1-mutated disease that progressed after at least 12 months of endocrine treatment plus a CDK4/6 inhibitor, under a commercial arrangement; the committee judged an acceptable ICER to be towards the upper end of £20,000 to £30,000 per QALY gained, the exact estimates are confidential, and the company model assumed £300 per digital polymerase chain reaction ESR1 test and a 50% ESR1-mutation prevalence, or £600 for each case identified for treatment. NICE states that it is “unable to make a recommendation about the use in the NHS of imlunestrant” because the company “does not intend to make an evidence submission for the evaluation”. For capivasertib plus fulvestrant compared with fulvestrant alone, U.S. analyses estimated $128,283.61 per QALY (0.62 incremental QALYs at an incremental cost of $79,117.66; U.S. health care perspective, 10-year horizon, $100,000 per QALY threshold), $280,854 per QALY (lifetime horizon, with a price reduction of nearly 70%, to $7000 per cycle, needed for cost-effectiveness), $636,455 per QALY gained in the PIK3CA/AKT1/PTEN-altered subgroup over 5 years in 2025 U.S. dollars (requiring a reduction from $28,332 to $5,598 per 4 weeks), and $709,647 per QALY in a fourth analysis. The CADTH (Canada) reimbursement review estimated $221,165 per QALY gained compared with endocrine monotherapy, stated that a price reduction of 85% would be required to reach $50,000 per QALY gained, and estimated a 3-year budget impact to public drug plans of $81,103,794, rising to $135,910,918 with 100% testing uptake. A U.S. budget impact analysis of second-line capivasertib in 2023 US dollars estimated 113, 114, and 115 eligible individuals per 1-million-member population in years 1 to 3, $31,939,838 in net costs over 3 years, and $0.88 per member per month. Alpelisib plus fulvestrant had an ICER of $340,153.30 per QALY gained from a U.S. payer perspective. In a 5-year analysis of patient-level data, CDK4/6 inhibitor use in the first line compared with the second line had healthcare costs of €61,821 and €39,057 and an ICER of €423,408 per QALY gained. No Institute for Clinical and Economic Review assessment of therapies for this population was identified.

U.S. payer cost-effectiveness analysis of elacestrant versus standard endocrine therapy in the second or third line

Drug cost parameters in the U.S. elacestrant model, US dollars

VariableBaseline valueRange, first boundRange, second bound
“ELA per mg”View highlighted excerpt for this quote“2.175”View highlighted excerpt for this quote“1.088”View highlighted excerpt for this quote“2.610”View highlighted excerpt for this quote
“FUL per 25mg”View highlighted excerpt for this quote“3.915”View highlighted excerpt for this quote“4.698”View highlighted excerpt for this quote“3.132”View highlighted excerpt for this quote
“Anastrozole per mg”View highlighted excerpt for this quote“0.107”View highlighted excerpt for this quote“0.086”View highlighted excerpt for this quote“0.128”View highlighted excerpt for this quote
“Exemestane per 25mg”View highlighted excerpt for this quote“0.713”View highlighted excerpt for this quote“0.571”View highlighted excerpt for this quote“0.855”View highlighted excerpt for this quote
“Letrozole per 2.5mg”View highlighted excerpt for this quote“0.106”View highlighted excerpt for this quote“0.085”View highlighted excerpt for this quote“0.127”View highlighted excerpt for this quote
“Subsequent treatment”View highlighted excerpt for this quote“9,061”View highlighted excerpt for this quote“7,248”View highlighted excerpt for this quote“10,873”View highlighted excerpt for this quote
“Administration”View highlighted excerpt for this quote“702”View highlighted excerpt for this quote“561”View highlighted excerpt for this quote“842”View highlighted excerpt for this quote

ICER review of therapies for ER-positive HER2-negative advanced breast cancer

No evidence found.

Eligible population input: number of women living with metastatic breast cancer in the United States

Cancer typeNew metastatic cases, 2018, de novo (observed)New metastatic cases, 2018, de novo and recurrence (estimated)Living with metastatic disease on January 1, 2018, de novo (observed)Living with metastatic disease on January 1, 2018, de novo and recurrence (estimated)
“Breast (female)”View highlighted excerpt for this quote“15 800”View highlighted excerpt for this quote“46 666”View highlighted excerpt for this quote“54 117”View highlighted excerpt for this quote“140 230”View highlighted excerpt for this quote

Comparator price: imlunestrant wholesale acquisition cost

Comparator price: elacestrant wholesale acquisition cost at launch

Name of prescription drugStrengthPack sizeWAC (as of date of commercial availability)Date of commercial availability
“Orserdu (elacestrant)”“86 mg”“30 tablets”“$7,123.00”“2/3/2023”
“Orserdu (elacestrant)”“345 mg”“30 tablets”“$21,369.00”“2/3/2023”

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.